Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CER-001 in Acute Coronary Syndrome
NCT02484378Phase 2Completed
- Sponsor
- ABIONYX Pharma
- Start
- Aug 2015
- Primary completion
- Nov 2016
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles
- Countries
- 4
01
Overview
A Phase 2 trial of CER-001 in acute coronary syndrome (ACS), sponsored by ABIONYX Pharma. Started Aug 2015; status: completed.
02
Drugs
CER-001
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT02484378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02484378.